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LEADING HEALTH CARE INNOVATION
W. Nicholson Price II, J.D., Ph.D.
W. Nicholson Price II, J.D., Ph.D., is an Academic Fellow  
at the Petrie-Flom Center for Health Law Policy, 
Biotechnology and Bioethics at Harvard Law School.
Problems of Innovation-Deficient 
Pharmaceutical Manufacturing
Physicians are usually focused on which drug 
to prescribe, but recent developments suggest 
that they should be looking at something they 
have long taken for granted: that their chosen 
drug is available, high quality, and free from 
contamination. Unfortunately, the pharmaceu-
tical industry has for decades lagged behind 
other industries, such as consumer goods, 
electronics, and food, in developing modern 
manufacturing processes, and today their pro-
cesses are expensive, inefficient, and riddled 
with problems. (http://www.amazon.com/
Pathway-Operational-Excellence-Pharmaceuti-
cal-Industry/dp/3871934003) This innovation 
deficiency has major negative impacts for pa-
tients, providers, the pharmaceutical industry, 
and the health care system as a whole. It also 
creates significant opportunities for firms 
willing to address technical and regulatory 
hurdles, although large-scale change will most 
likely demand legal and regulatory solutions.
Manufacturing is a far larger cost driver for 
the pharmaceutical industry—and, conse-
quently, for the health care system—than is 
commonly appreciated. Even large, research-
oriented drug makers spend about 26% of 
their revenues on manufacturing—approxi-
mately twice what they spend on research and 
development—and generic firms spend an av-
erage of 52%. (http://link.springer.com/article/
10.1007%2Fs12247-008-9024-4) The wide-
spread perception that manufacturing is inex-
pensive is probably driven by the low marginal 
costs of high-volume blockbuster drugs, but 
the industry also has high fixed costs, high 
compliance and quality costs, and higher mar-
ginal costs for other drug types. The industry 
spends approximately $200 billion annually on 
manufacturing, and process inefficiencies ac-
count for a large fraction of that total.
Despite the expense of making drugs, 
manufacturers frequently churn out their 
products for decades using the same pro-
cesses, without modernizing techniques to 
improve efficiency or product quality. (http://
www.nature.com/clpt/journal/v93/n2/full/ 
clpt2012220a.html) Continuous process im-
provement, which has proved central to high-
quality manufacturing in other industries, is 
restrained in the drug industry by regulatory 
barriers to change—most straightforwardly, 
by the procedural barriers of manufacturing 
supplement filings and preapproval require-
ments for major changes—and by an industry 
mindset that resists altering regulator-ap-
proved and validated procedures. At least 
partly as a result of outdated manufacturing 
techniques, an estimated 7 to 16% of drugs 
must be discarded before sale because they fail 
predistribution testing. (http://www.amazon.com/
Pathway-Operational-Excellence-Pharmaceutical 
-Industry/dp/3871934003) Keeping plants un-
modified for decades also promotes neglect; 
Food and Drug Administration (FDA) Warning 
Letters describe plants with rusty tools in ster-
ile areas, ceiling leaks, the presence of mold, 
and numerous other violations. (http://www.
nytimes.com/2012/10/18/business/drug-makers 





The innovation deficiency manifested in old 
plants and outdated manufacturing processes, 
and the attendant problems with drug quality, 
contribute to major problems in the health 
care system, including recalls, related con-
tamination events, and drug shortages affect-
ing both brand-name and generic products.
Manufacturing problems have spawned an 
increasing number of dramatic quality fail-
ures. 2011 saw over 2000 drug recalls, the vast 
majority from contamination during manufac-
turing or packaging or from other manufac-
turing problems, including cracked glass sy-
ringes, penicillin cross-contamination, 
stainless steel particulates in injectables, and 
packages with tablets from multiple drugs. 
(http://www.pharmamanufacturing.com/ 
articles/2012/159/) Recent high-profile in-
stances have included the shipment and subse-
quent recall of overfilled vials of morphine 
made by Hospira and bacterially contaminated 
propofol made by Teva. Some quality problems 
are expected and unavoidable, but many result 
from insufficiently controlled manufacturing 
facilities and the failure to develop and imple-
ment innovative techniques for continuous 
monitoring and recalibration. When processes 
are held static for decades rather than updat-
ed, the expected entropic drift of process pre-
cision and parameters is likely to lead to de-
creases in quality rather than steady-state 
quality maintenance.
Drug manufacturing problems have also 
been linked to increasing shortages of drugs, 
including several front-line chemotherapeu-
tics. (http://www.nature.com/clpt/journal/v93/
n2/full/clpt2012220a.html) For sterile paren-
teral drugs, which made up 73% of shortages 
in 2011, 56% of shortages were directly caused 
by manufacturing quality problems and an ad-
ditional 20% were caused by capacity issues or 
manufacturing delay. The direct cause of an-
other 16% was shortages of related drugs or 
voluntary discontinuance, but each of those 
causes frequently results from manufacturing 
problems. Particularly for drugs with tight 
supply chains, plant shutdowns to remedy 
quality problems, whether voluntary or FDA-
mandated, can easily lead to overall shortages 
or to supply-chain disruptions that generate 
regional or institution-specific shortages.
These problems directly impact patients, 
providers, drug companies, and the health 
care system. Any patient who takes contami-
nated drugs or whose treatment is altered, 
postponed, or suspended owing to drug short-
ages is clearly negatively affected by manufac-
turing quality concerns. In addition, patient 
confidence in the drug-production system may 
be broadly damaged by high-profile quality 
failures. Providers, especially oncologists, al-
ready cope with the problems of drug short-
ages and may need to weigh manufacturer 
quality when prescribing drugs, particularly if 
recalls and other quality problems continue to 
increase. Pharmaceutical companies risk the 
potential loss of consumer confidence in drug 
quality, adding to other reputational threats 
that already face the industry. Finally, the 
health care system as a whole faces substantial 
costs from both shortages and recalls, as well 
as far greater costs from drug prices that are 
increased by inefficient and overly expensive 
manufacturing methods.
Direct regulatory oversight is only part of 
the solution for quality issues- and even less 
for the underlying innovation problems. The 
FDA and other regulators—including the Eu-
ropean Medicines Agency, Health Canada, in-
ternational inspectors from other Organiza-
tion for Economic Cooperation and 
Development countries, and overseas manu-
facturers’ domestic regulators—have a limited 
number of inspectors with which to oversee a 
complicated and highly globalized supply 
chain. For shortages in particular, regulatory 
oversight, quality lapses, and lack of available 
drugs interact: regulatory actions to ensure 
compliance with manufacturing-quality regu-
lations and prevent quality problems and loss 
of drug availability can themselves close plants 
and lead to shortages. To address this interac-
tion, the FDA Safety and Innovation Act of 
2012 requires that the FDA take the potential 
for shortages into account before initiating 
regulatory action in response to manufactur-
ing problems. Thus, the FDA’s greatest regula-
tory threat—shutting down a plant—is diffi-
cult to deploy prospectively or to use as a 
credible threat. More broadly, FDA oversight 
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can identify problems but cannot itself readily 
drive innovation. While manufacturers may 
spend hundreds of millions of dollars to fix 
specific problems at the plants that the FDA 
does shut down, those fixes fail to resolve the 
structural problems that limit industry innova-
tion and cause quality problems in the first 
place.
The causes of innovation deficits in phar-
maceutical manufacturing are complex. They 
include an industry culture in which manufac-
turing, unlike investments in research and 
development or sales and marketing, has not 
been seen as a source of competitive advan-
tage, regulatory barriers to introducing new 
technology or changing manufacturing tech-
niques, and an absence of effective incentives 
for manufacturing innovation in the patent 
system or from other sources. Eventual solu-
tions will be accordingly complex as well. In 
addition to changes in corporate focus, they 
will most likely require regulatory reform and 
perhaps greater incentives that reward innova-
tion in manufacturing. FDA officials have al-
ready proposed steps to target drug-manufac-
turing quality, including FDA’s Quality by 
Design initiative, an increased regulatory fo-
cus on quality, and the possibility of leverag-
ing market incentives by providing manufac-
turer quality grades to consumers. (http://
www.nature.com/clpt/journal/v93/n2/full/ 
clpt2012220a.html) In addition to these quali-
ty-directed reforms, the FDA could potentially 
change intellectual-property incentives for in-
novation through regulatory channels as cur-
rently helps shape patent incentives for drug 
discovery and development. The FDA’s current 
approaches will probably help to improve drug 
quality, but other creative methods are needed 
to increase manufacturing innovation. To find 
and implement such wide-reaching solutions, 
the medical and pharmaceutical communities 
must first recognize that drug manufacturing, 
rather than an afterthought, is in fact a locus 
of major health care problems and needs seri-
ous and sustained attention.
